Oncotech

The bank, formerly owned by Oncotech, contains more than 144,000 discrete cancer samples.

No mention was made of a number of other miRNA diagnostics projects, suggesting that the Danish company has put these on hold as part of a scale-back of its efforts in the area.

Despite the setback, Exiqon remains on track with its strategy of marketing its microRNA-based diagnostics in collaboration with partners, and expects to announce a deal before the end of the year, a company official said.

The company also reported its financial results for 2009, posting a slight increase in its net loss for the year, which included the impact of operations from its now-discontinued Oncotech unit.

The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.

In its annual report, Exiqon also indicated that it would eventually seek US Food and Drug Administration approval for its miRNA diagnostics so that they could be made available to a broader range of laboratories and pathologists.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.